Harbin Pharmaceutical Group Co Ltd China's second-biggest drug maker by market value, announced yesterday that its net profit rose 2.42% year on year to RMB 269 million in the third quarter of this year, sources reported.
In the reporting period, its revenue surged 22.11% year on year to RMB 3.21 billion, with earnings per share of RMB 0.22, up 2.41% from a year earlier.
The company's revenue and net profit in the first nine months of this year was RMB 9.77 billion and RMB 833 million, up 21.61% and 14.58% compared with the same period of last year. Its EPS increased 14.59% to RMB 0.67.
Harbin Pharmaceutical promised to invest at least RMB 2.61 billion to support the firm's future development.
In the reporting period, its revenue surged 22.11% year on year to RMB 3.21 billion, with earnings per share of RMB 0.22, up 2.41% from a year earlier.
The company's revenue and net profit in the first nine months of this year was RMB 9.77 billion and RMB 833 million, up 21.61% and 14.58% compared with the same period of last year. Its EPS increased 14.59% to RMB 0.67.
Harbin Pharmaceutical promised to invest at least RMB 2.61 billion to support the firm's future development.
No comments:
Post a Comment